Vol 2024, No 3 (2024)

Table of Contents

Research & Development

Merck KGaA Pays C4 Therapeutics US$16 M Upfront for Protein Degraders Abstract pdf html
Lucy Haggerty
Gilead Collaborates with Merus For Novel Antibody-Based Trispecific T-Cell Engagers Abstract pdf html
Lalit Mishra
Boehringer Ingelheim Collaborates with Sosei Heptares for Antipsychotic Drugs Abstract pdf html
Amit Kaushik

Mergers & Acquisitions

Gilead to Acquire CymaBay Therapeutics and its Liver Disease Drug for US$4.3 B Abstract pdf html
Lucy Haggerty
AstraZeneca Buys Fusion Pharmaceuticals for US$2 B Abstract pdf html
Lucy Haggerty

Opinion & Analysis

IQVIA Pharma Deals Review of 2023 Abstract pdf
Lucy Haggerty, Ayush Saxena & Taskin Ahmed


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.